newsfilter
← Latest News
Business Wire·

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

-Phase 1b Study in CKD Patients to begin early 2025- Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of